




A




B



C



D



D

Supplementary Figure S5. Nivolumab did not significantly affect peripheral NKs and Tregs. (A) Distribution of NKs-NK^{dim}-NK^{bright} (n=45); activating receptor: NKG2D⁺NKs (n=19), NKp46⁺NKs (n=24), NKp44⁺NKs (n=30), NKp30⁺NKs (n=26); inhibitory receptors: KLRB1⁺NKs (n=41), KIR2DL1⁺NKs (n=42), KIR2DL2/DL3⁺NKs (n=39); PD-1⁺NKs (n=41). (B) Analysis of CD107a degranulation over time. (C) Distribution of Tregs (n=51) and Treg markers: CTLA-4⁺Tregs (n=37), PD-1⁺Tregs (n=45), ICOS⁺Tregs (n=28), Helios⁺Tregs (n=37), ENTPD1⁺Tregs (n=46), CXCR4⁺Tregs (n=49). (D) CFSE-Teff proliferation/Tregs (n=48). Box plot showing the data distribution across groups with minimum, median, and maximum value. Two-tailed test comparison of differences between two independent groups (*p<0.05; **p<0.01; ***p<0.001).